Leishmaniasis (visceral and cutaneous), Chagas disease and human African
trypanosomiasis cause substantial death and morbidity, particularly in low-and middle …

Leishmaniasis is a vector-borne parasitic disease caused by Leishmania species. The
disease affects humans and animals, particularly dogs, provoking cutaneous …

Tritryps diseases are devastating parasitic neglected infections caused by Leishmania spp.,
Trypanosoma cruzi and Trypanosoma brucei subspecies. Together, these parasites affect …

Although there have been significant advances in the treatment of visceral leishmaniasis
(VL) and several novel compounds are currently in pre-clinical and clinical development for …

Leishmaniasis, a tropically neglected disease, is responsible for the high mortality and
morbidity ratio in poverty-stricken areas. Currently, no vaccine is available for the complete …

Leishmaniasis (Leishmania species), sleeping sickness (Trypanosoma brucei), and Chagas
disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by …

Developing anti-parasitic lead compounds that act on key vulnerabilities are necessary for
new anti-infectives. Malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis and coccidiosis …

American cutaneous leishmaniasis is a zoonotic disease caused by protozoans of the genus
Leishmania. The treatment of cutaneous leishmaniasis is unsatisfactory, thus, much …

The main challenges associated with leishmaniasis chemotherapy are drug toxicity, the
possible emergence of resistant parasites, and a limited choice of therapeutic agents …

Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania
RNA virus 1 (LRV1), which has been associated with increased disease severity in animal …